Portal Hypertension VI

Part I. Risk Stratification and Prognosis

1. Introduction: Baveno I to Baveno VI.... and Beyond
Roberto Franchis

2. The Concept of Risk Stratification
Jayant A. Talwalkar

3. Competing Risks and Prognostic Stages in Cirrhosis
Gennaro D’Amico

Part II. Screening and Surveillance: Invasive and Noninvasive Methods

4. Results of the Questionnaire
Bogdan Procopet, Annalisa Berzigotti

5. Identifying Compensated Advanced Chronic Liver Disease: When (Not) to Start Screening for Varices and Clinically Significant Portal Hypertension
Salvador Augustin, Mónica Pons, Begoña Santos, Meritxell Ventura, Joan Genescà

6. How to Screen?
Laurent Castera

7. When and How to Perform Surveillance
Avik Majumdar, Massimo Pinzani

8. Cost Considerations
Thomas D. Boyer

9. Consensus Statements: Session 1—Screening and Surveillance
Annalisa Berzigotti, Thomas Boyer, Laurent Castera, Massimo Pinzani, Roberto Franchis, Joan Genescà

Part III. Changing Scenarios I: Impact of Etiological Therapy for Cirrhosis and of Anti-fibrotic Therapy on Portal Hypertension

10. (Pre)Primary Prophylaxis: Where Were We and Where Are We Heading?
Alexander Zipprich

11. Defining Clinical Hints to Predict Decompensation and Altering Paradigm in Patients with Cirrhosis
Maria Kalafateli, Emmanuel A. Tsochatzis

12. Antiviral Treatments and Residual Risk of Hepatic Decompensation
Markus Peck-Radosavljevic

13. Etiological Treatments: Lifestyle Management
Rafael Bañares, Luis Ibáñez-Samaniego

14. Liver Fibrosis: What Is Reversible and What Not? How to Assess Regression?
Virginia Hernández-Gea

15. Potential Antifibrotic Therapies: Approaching the Bedside: Proof-of-Concept Studies (Part 1)
Wim Laleman

16. New Targets in Therapy: Statins, Antioxidants and Antiangiogenic Strategies
Jaime Bosch, Jordi Gracia-Sancho

17. Consensus Statements: Session 2—Impact of Etiological and Anti-fibrotic Therapy
Jaime Bosch, Rafael Bañares, Virginia Hernandez-Gea, Markus Peck-Radosavljevic, Emmanouil A. Tsochatzis, Alexander Zipprich, Wim Laleman

Part IV. The Gut Microbiome and Cirrhosis

18. The Gut Microbiome and Cirrhosis: Basic Aspects
Reiner Wiest

19. The Gut Microbiome and Cirrhosis: Clinical Aspects
Jasmohan S. Bajaj

Part V. Changing Scenarios II: What to Do After Successful Cure of the Etiologic Factor

20. Result of the Questionnaire
Carlo Merkel, Aleksander Krag

21. Introduction: Prevention of Decompensation Versus Prevention of First Bleeding
Aleksander Krag, Carlo Merkel

22. Role of Comorbidities in the General Management of Compensated Cirrhosis, Including Malnutrition
Marika Rudler, Vincenzo Mura

23. Primary Prophylaxis of First Variceal Bleeding
Manuela Merli, Roberto J. Groszmann

24. Endoscopic Band Ligation in Primary Prophylaxis
Àngels Escorsell, Julio D. Vorobioff

25. Consensus Statements: Changing Scenarios: Prevention of Decompensation
Aleksander Krag, Àngels Escorsell, Roberto Groszmann, Vincenzo Mura, Manuela Merli, Marika Rudler, Julio D. Vorobioff, Carlo Merkel

Part VI. Management of the Acute Bleeding Episode

26. Management of Acute Variceal Bleeding in Patients with Cirrhosis: General Management, Drug Therapy, and Endoscopic Treatment
Puneeta Tandon, Ian M. Gralnek, Gin-Ho Lo, Lars Aabakken, Frederik Nevens, Juan Carlos Garcia-Pagán

27. A la Carte Treatment of Acute Variceal Bleeding
Càndid Villanueva, James O’Beirne, Christophe Bureau, Dominique Thabut

28. Consensus Statements: Management of the Acute Bleeding Episode
Juan Carlos Garcia-Pagàn, Lars Aabakken, Christophe Bureau, Ian Gralnek, Gin Ho Lo, Frederik Nevens, James O’Beirne, Puneeta Tandon, Candid Villanueva, Dominique Thabut

Part VII. Controversies and Challenges in Pediatrics

29. Portal Hypertension in Pediatrics: Controversies and Challenges 2015 Report
Benjamin L. Shneider

Part VIII. Prevention of Further Decompensation (Ascites, Spontaneous Bacterial Peritonitis, Hepatorenal Syndrome, Hepatic Encephalopathy)

30. Introduction and Survey Results
Guadalupe Garcia-Tsao, Cristina Ripoll, Salvador Augustin, Thomas Reiberger, Agustin Albillos, Richard Moreau, Francesco Salerno, Juan G. Abraldes

31. Prevention of Variceal Rebleeding: Stratifying Risk and Individualizing Care
Agustin Albillos, Juan G. Abraldes, Cristina Ripoll, Thomas Reiberger, Salvador Augustin, Francesco Salerno, Richard Moreau, Guadalupe Garcia-Tsao

32. Secondary Prophylaxis in Special Patient Populations
Thomas Reiberger, Richard Moreau, Cristina Ripoll, Agustin Albillos, Salvador Augustin, Francesco Salerno, Juan G. Abraldes, Guadalupe Garcia-Tsao

33. Effect of Current Therapies Aimed at Preventing Variceal Rebleeding on Other Complications of Cirrhosis
Cristina Ripoll, Salvador Augustin, Thomas Reiberger, Richard Moreau, Francesco Salerno, Agustin Albillos, Juan G. Abraldes, Guadalupe Garcia-Tsao

34. Impact of Treatment of Non-bleeding Complications of Cirrhosis on the Risk of Variceal Bleeding
Salvador Augustin, Agustin Albillos, Cristina Ripoll, Juan G. Abraldes, Francesco Salerno, Richard Moreau, Thomas Reiberger, Guadalupe Garcia-Tsao

35. Issues in Trial Design and Areas Needing Further Research
Juan G. Abraldes, Francesco Salerno, Salvador Augustin, Cristina Ripoll, Thomas Reiberger, Richard Moreau, Agustin Albillos, Guadalupe Garcia-Tsao

36. Consensus Statements: Preventing Recurrent Variceal Hemorrhage and Other Decompensating Events
Juan G. Abraldes, Augustin Albillos, Salvador Augustin, Richard Moreau, Thomas Reiberger, Cristina Ripoll, Francesco Salerno, Guadalupe Garcia-Tsao

Part IX. Vascular Diseases of the Liver in Cirrhotic and Non-cirrhotic Portal Hypertension: Coagulation, Anti-coagulation, Anti-platelet Drugs

37. Results of the Questionnaire
Massimo Primignani

38. Extrahepatic Portal Vein Obstruction (EHPVO) and Idiopathic Portal Hypertension: East Versus West
Shiv K. Sarin, Cyriac Abby Philips

39. Budd-Chiari Syndrome/Hepatic Venous Outflow Tract Obstruction: East vs West
Dominique-Charles Valla

40. Antithrombotic Treatment in Cirrhosis
Frank W. G. Leebeek

41. Session 6: Consensus Statements – Vascular Diseases of the Liver in Cirrhotic and Noncirrhotic Portal Hypertension
Jonel Trebicka, Andrea Gottardi, Alessandra Dell’Era, Frank Leebeek, Shiv Sarin, Susana Seijo, Dominique Valla, Massimo Primignani

42. Erratum to: Chapter 9 in Consensus Statements: Session 1—Screening and Surveillance
Annalisa Berzigotti, Thomas Boyer, Laurent Castera, Massimo Pinzani, Roberto Franchis, Joan Genescà

Avainsanat: Medicine & Public Health, Hepatology, Life Sciences, general